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PDI (protein disulfide-isomerase) catalyses the formation of
native disulfide bonds of secretory proteins in the endoplasmic
reticulum. PDI consists of four thioredoxin-like domains, of
which two contain redox-active catalytic sites (a and a′), and
two do not (b and b′). The b′ domain is primarily responsible
for substrate binding, although the nature and specificity of
the substrate-binding site is still poorly understood. In the
present study, we show that the b′ domain of human PDI is in
conformational exchange, but that its structure is stabilized by the
addition of peptide ligands or by binding the x-linker region.
The location of the ligand-binding site in b′ was mapped by
NMR chemical shift perturbation and found to consist primarily
of residues from the core β-sheet and α-helices 1 and 3. This site
is where the x-linker region binds in the X-ray structure of b′x
and we show that peptide ligands can compete with x binding at
this site. The finding that x binds in the principal ligand-binding
site of b′ further supports the hypothesis that x functions to gate
access to this site and so modulates PDI activity.
Key words: b′ domain, ligand-binding site, nuclear magnetic
resonance (NMR), protein disulfide-isomerase (PDI).
INTRODUCTION
PDI (protein disulfide-isomerase) is a key enzyme responsible for
the formation of native disulfide bonds in proteins that enter the
secretory pathway of eukaryotic cells. PDI is a multifunctional
protein able to catalyse the oxidation and isomerization of
disulfide bonds, as well as to bind to unfolded proteins and act
as a molecular chaperone [1]. The isomerization of incorrectly
paired cysteine residues is often a rate-limiting step on the
folding pathway of disulfide bond-containing proteins both
in vitro and in vivo [2–4]. The ability of PDI to combine redox
and molecular chaperone-like activities allows it to bind to partly
structured folding intermediates and to catalyse simultaneously
protein folding and associated native disulfide bond formation
[5]. PDI is the archetype of a large family of ER (endoplasmic
reticulum)-resident PDI-like proteins [6].
PDI contains four thioredoxin-like domains, two of which, like
thioredoxin itself, have redox-active catalytic sites (a and a′) and
two of which do not (b and b′). The domain order is a-b-b′-x-
a′-c, where x is a 19-residue linker between the b′ and a′ domains
[7] and c is a C-terminal acidic tail containing the KDEL (Lys-
Asp-Glu-Leu) ER-retention signal. The a and a′ domains are
responsible for the redox activity of PDI, whereas the b′ domain
has been shown to be essential for ligand binding [8]. The b′
domain binds both small and large peptide ligands, although large
ligands also require the a and a′ domains to contribute to the
overall binding interaction [8,9]. The b′ domain is likely to control
the substrate specificity of PDI and is known to be required for
disulfide isomerization reactions in protein substrates [10]. In
ERp57, a PDI family member that is specific for the lectin-like
molecular chaperones calnexin and calreticulin, the b′ domain
contains the binding site for these proteins allowing the lectins
to recruit nascent glycosylated polypeptides to the isomerase to
facilitate folding [11,12].
PDI has proved to be a difficult protein for three-dimensional
structure determination. The first structure for a full-length
PDI (yeast Pdi1p) was not published until 2006 [13], although
abundant protein from a variety of sources has been available for
many years. This structure was obtained from crystals of yeast
Pdi1p grown at 4 ◦C and revealed a twisted U-shaped molecule
where the b and b′ domains make up the valley floor and the a
and a′ domain are positioned either side with their redox-active
catalytic sites facing one another across the central cleft. The U is
lined with hydrophobic residues thought to constitute the ligand-
binding site. The b′ domain provides the core of this put-
ative binding site, with the a and a′ domains contributing
hydrophobic residues around their active sites. The b domain
extends the hydrophobic site on b′ and may be important
for binding larger molecules. A second crystal form of yeast
Ppi1p grown at a higher temperature has shown that the full-
length molecule is conformationally flexible with respect to the
orientation and position of the a domain to the rest of the molecule
[14]; such flexibility will tend to prevent regular crystal formation.
Single domain structures for domains a and b of human PDI
were determined by NMR more than 10 years ago [15,16], and
a structure of the isolated a′ domain has been deposited in
the Protein Data Bank (PDB code 1X5C), but there has been
no reported NMR structure for the independent b′ domain of
human PDI. However, recently, six three-dimensional structures
of mammalian PDI family members containing a b′ domain have
been published (full-length ERp44 [17], full-length ERp57 in a
complex with tapasin [18], bb′ domains of ERp57 and ERp72
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[12,19], and b′x and bb′ domains of human PDI [20,21]). In two
of these structures, a hydrophobic site similar to that seen in the
b′ domain of yeast has been identified into which another part of
the polypeptide chain is bound (the x-linker region in b′x [20]
and the C-terminal region in ERp44 [17]). These findings suggest
that access to the core ligand-binding site can be gated by a
capping structure within the protein, leading to the possibility of
high- and low-ligand-affinity states.
To date there are no published structures of PDI with bound
peptide ligands or unfolded protein substrates and hence the
ligand-binding site has not been identified directly. In the present
study, we have used NMR chemical shift perturbation to map
the ligand-binding site in the b′ domain of human PDI and have
shown that peptide ligands can compete with the x-linker region
for binding at this site. We also show that the neighbouring b
domain and x-linker region stabilize the structure of b′ and that
the b domain has an effect on the ligand-binding site, even though
this site is distant from the b–b′ domain–domain interface.
MATERIALS AND METHODS
Recombinant protein expression and purification
Human PDI fragments comprising b′ (Pro218–Gly332), b′x (Lys213–
Pro351), bb′ (Ala119–Gly332) and bb′x (Ala119–Pro351) were ex-
pressed from pET23b (Novagen) in Escherichia coli BL21(DE3)-
pLysS cells with an N-terminal His6 tag (MHHHHHHM). E. coli
cultures were grown at 37 ◦C in M9 minimal medium containing
either [15N]ammonium sulfate or [15N]ammonium sulfate and
[13C]glucose and induced with 1.0 mM IPTG (isopropyl β-D-
thiogalactoside) for 4 h to generate uniformly 15N-labelled and
15N/13C-labelled protein.
For protein purification, cells were harvested by centrifugation
at 6200 g for 15 min and resuspended in 20 mM sodium phosphate
buffer (pH 7.3) (buffer A), containing DNase (10 μg/ml) before
freezing at −20 ◦C. Thawed cell lysate was clarified by
centrifugation at 17400 g for 15 min and loaded on to a column
of nickel-chelating Sepharose (GE Healthcare). The column was
washed with buffer A containing 25 mM imidazole and 0.5 M
NaCl following by buffer A alone, and then the recombinant
product eluted with buffer A containing 50 mM EDTA. The
eluted protein was dialysed against buffer A or diluted 5× with
buffer A before loading on to a Source 30Q ion-exchange column
(GE Healthcare). Bound proteins were separated with a linear
gradient of 0–500 mM NaCl over 20 column volumes. Fractions
were pooled based on SDS/PAGE analysis and concentrated by
ultrafiltration (5 kDa cut-off for single domain constructs, 10 kDa
cut-off for larger constructs).
b′x and bb′x constructs were purified further by gel-filtration
chromatography. Samples were separated on Superdex 75 or
200 columns (2.6 cm×55 cm, GE Healthcare) in 20 mM sodium
phosphate buffer (pH 7.1) containing 150 mM NaCl. Fractions
corresponding to monomer and dimer were well-resolved and
were pooled separately.
To prepare triple-labelled (2H, 13C, 15N) bb′x, a single colony of
cells carrying the bb′x expression plasmid was grown overnight in
20 ml of M9 minimal medium; cells were then pelleted and resus-
pended in 40 ml of M9 minimal medium containing 35% 2H2O.
Cells from this culture were collected and stored in 40% glycerol,
and the process of adaptation was repeated stepwise using
successive cultures in 65, 86, 91, 94 and 96% 2H2O. Cells adapted
to growth in 96% 2H2O were streaked on an LB (Luria–Bertani)
agar plate with appropriate antibiotics to enable selection of a
single colony to inoculate a 50 ml starter culture of M9 minimal
medium containing 96% 2H2O, [15N]ammonium sulfate and
[13C]glucose supplemented with 10% Spectra 9 (Spectra Stable
Isotopes), a rich medium containing 2H (>97%), 13C (>98%)
and 15N (>98%). After overnight growth, this starter culture
was used to inoculate two 400 ml cultures of the same medium
and these cultures grown to a D600 of 0.6 before induction with
1.0 mM IPTG for 6 h. The labelled bb′x protein was recovered
and purified as described above. The mass of the purified product
was determined to be 30180 Da, implying 63% labelling with 2H
(81% labelling of non-exchangeable 1H) if the labelling efficiency
with 13C and 15N was 96% as determined in previous experiments
in water.
NMR spectroscopy
NMR samples were typically 0.5–1.5 mM protein in 20 mM
sodium phosphate buffer containing 100 or 150 mM NaCl
(pH 6.5) and 10% (v/v) 2H2O in a final volume of 330 μl.
Unless stated otherwise, NMR experiments were performed
at 600 MHz using a Varian Unity INOVA equipped with a
5 mm HCN z-pulse field gradient probe. All NMR experiments
were solvent-suppressed to reduce the water signal using the
WATERGATE method [22], and all indirect NMR dimensions
[non-TROSY (transverse relaxation optimized spectroscopy)
experiments] were acquired using the hypercomplex method.
15N/1H-HSQC (heteronuclear single-quantum coherence) spectra
were collected at 25 and 40 ◦C as described by Alanen et al. [23].
Backbone chemical shift assignment for b′x (at 25 ◦C) and bb′x
(at 40 ◦C) were carried out using three-dimensional CBCANH
and CBCA(CO)NH experiments [24,25]. Assignments for bb′x
were also confirmed by analysis of three-dimensional TROSY-
HNCA and TROSY-HN(CO)CA experiments acquired at 800
MHz (Varian Unity INOVA) and 25 ◦C on a deuterated sample
prepared as described above. Backbone assignments for b were
taken from the BioMagResBank (accession code 4156 [26]) and
the assignments confirmed and mapped on to an 15N/1H-HSQC
spectrum of b collected under the same experimental conditions
as the other constructs by analysis of 15N HSQC-TOCSY and
15N-HSQC-NOESY spectra. All NMR data were processed using
NMRPipe [27], and spectra were analysed manually using the
CCPN Analysis software package [28].
Peptide ligands
-Somatostatin (AGSKNFFWKTFTSS [8]) and KFWWFS were
generated by peptide synthesis and purified by reverse-phase
HPLC. Peptide was added at a 2-fold molar excess over target
protein concentration unless stated otherwise.
RESULTS
Expression and purification of b′, b′x, bb′ and bb′x
PDI domain fragments were purified by a combination of nickel-
affinity and anion-exchange chromatography. b′x and bb′x often
gave complex or asymmetric peak profiles during ion-exchange
chromatography (Figure 1a), suggesting the presence of two or
more forms, although SDS/PAGE and electrospray ionization–
MS analysis on fractions taken across the peak revealed only a
single protein species at the correct molecular mass (Figure 1a,
inset). Subsequent analysis of ion-exchange-purified material by
gel-filtration chromatography found that preparations of b′ and
bb′ resolved as a single peak (results not shown). In contrast,
b′x and bb′x both resolved as two peaks of approximately equal
magnitude (Figure 1b). These subfractions represent dimeric
and monomeric forms of b′x and bb′x, whereas b′ and bb′
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Figure 1 Purification of b′x
(a) Typical asymmetric ion-exchange profile of b′x with SDS/PAGE analysis of fractions taken
across the peak shown in the inset (molecular masses are indicated in kDa). The broken line
(right-hand axis) indicates the salt gradient used for elution (0−0.5 M NaCl). (b) Gel-filtration
chromatography of the b′x peak shown in (a). b′x resolves into two peaks identified as
homodimer (A) and monomer (B). mAu, milli-absorbance units.
are found exclusively as dimeric species. Both b′x and bb′x
contain a unique tryptophan residue in the x-linker region of
the fragment, and fluorescence analysis of the monomeric and
dimeric forms revealed spectra similar to those seen previously
for the ‘capped’ and ‘uncapped’ forms of b′x respectively [20].
We have previously determined the structure of the capped form
of b′x using X-ray crystallography. This structure shows the x-
linker bound in a hydrophobic patch on the surface of b′ [20].
The monomeric fractions of b′x and bb′x gave well-resolved
NMR spectra, consistent with folded proteins (Figures 2a and 2b).
All the work in the present study was carried out using purified
samples of monomeric b′x and bb′x and dimeric b′ and bb′.
Backbone assignment of b′x and bb′x
Backbone assignments were obtained from standard triple-
resonance datasets acquired at 25 ◦C for b′x and 40 ◦C for
bb′x (the elevated temperature for bb′x was to compensate for
signal reduction from increased NMR relaxation rates owing
to the higher molecular mass of this construct). Backbone
assignments for bb′x were confirmed by analysis of TROSY-
HNCA and TROSY-HN(CO)CA experiments using an 81%
non-exchangeable deuterated sample. A series of 15N/1H-HSQC
experiments for bb′x at 40, 35, 30 and 25 ◦C enabled extrapolation
of assignments for comparison with b′x chemical shift data at
25 ◦C. Assignments for both constructs have been deposited in
the BioMagResBank (accession codes 15998 and 15974 for b′x
and bb′x respectively).
Figure 2 15N/1H-HSQC spectra of (a) b′x, (b) bb′x (c) b′, (d) bb′, (e)
b′ +KFWWFS and (f) bb′ +-somatostatin
All spectra were collected at pH 6.5 and 25◦C. b′ and bb′ were found to be exclusively dimeric
on purification, whereas b′x and bb′x were found to be both dimeric and monomeric (only
spectra for the monomeric form shown here). Some 20 non-overlapping peaks common to
b′/b′x or bb′/bb′x spectra were used to estimate average F2 line width at half peak height.
The estimates obtained were: b′x= 20.1 Hz, bb′x= 24.0 Hz, b′ >40 Hz, bb′ = 36.9 Hz,
b′ + KFWWFS=18.5 Hz and bb′ +-somatostatin=26.4 Hz.
Backbone assignment for the x-linker region in both constructs
proved to be more challenging than for the rest of the molecule
with resonances weak or lacking from the CBCANH and/or
CBCA(CO)NH experiments. In b′x, two assignment pathways
were observed for residues Met339–Gln350, suggesting at least two
structural forms for this region. One pathway consisted of sharp
well-resolved peaks; the second pathway consisted of broader
peaks more typical in line width to those of the rest of the protein.
These two sets of peaks are believed to originate respectively from
a (freely mobile) unbound x-linker region and a bound form of x
which interacts with a site on the b′ domain. In contrast, the bb′x
spectra revealed only one detectable assignment pathway for the
x-linker region, although a few unassignable peaks remain in
the spectra. The line widths for the peaks in the assigned pathway
were narrower compared with the rest of the protein, suggesting
that they originate from an unbound form of x. Furthermore,
the last five residues (Asp346–Gln350) had comparable backbone
chemical shifts with unbound x in b′x. The signals from an
unbound x-linker region are thought to arise from small amounts
of uncapped dimer contaminating the samples. Uncapped x gives
a characteristic high-field indole amide peak which can be seen in
c© The Authors Journal compilation c© 2009 Biochemical Society
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the 15N/1H-HSQC spectra (1HN = 10.13p.p.m., 15N=129.8p.p.m.;
Figure 2b). The sharp resonances of the uncapped x-linker region
allow it to be detected easily, even when in relatively low amounts.
Effect of peptide ligands on the structure of b′ and bb′
The NMR spectra for dimeric b′ and bb′ were poor and their
broad line widths prevented backbone assignment (Figures 2c
and 2d). However, in the presence of a peptide ligand (Fig-
ures 2e and 2f), the line shape, resolution and dispersion of
these spectra improved markedly, suggesting dissociation of
the dimeric form to generate monomers, together with possible
ligand-dependent stabilization of the b′ structure reducing any
line-broadening from conformational exchange. The hydrophobic
peptide KFWWFS was found to have a significant effect on b′
(compare Figures 2c and 2e), giving spectra with line widths com-
parable with capped b′x (Figure 2a; average line widths given
in the legend to Figure 2), but this ligand proved to be very
difficult to handle reliably owing to its poor solubility. An
alternative ligand, -Somatostatin [8], was used for studies with
bb′, and this ligand also had a significant effect on the line
widths (compare Figures 2d and 2f), giving values approaching
those seen for capped bb′x (Figure 2b). -Somatostatin was
also seen to improve the quality of spectra when added to b′,
but the effect was less marked than when added to bb′ at the
same concentration and significantly poorer than that seen with
KFWWFS (results not shown). Experiments were also carried
out with the small hydrophobic molecule 2-propylphenol that had
been shown previously to interact with the b′ domain of PDI [29].
This molecule was seen to improve the spectrum of b′ (results not
shown), with average line widths decreasing to 24.4 Hz.
Mapping of the b′ ligand-binding site
Chemical shift perturbation can be estimated, when comparing
spectra where only one of the spectra has been fully assigned,
by measuring distances from signals in the assigned spectrum
to the nearest peak in the unassigned spectrum. This approach
was used to identify the ligand-binding site in b′ by comparing
the assigned 15N/1H-HSQC spectrum of b′x with b′ + KFWWFS
and the assigned spectrum of bb′x with bb′ +-somatostatin.
The direct comparison of b′ with b′ + KFWWFS or bb′ with
bb′ +-somatostatin was not possible because of the poor quality
of the unliganded spectra (Figures 2c and 2d). The -somatostatin
ligand was also seen to bind to b′x as judged by peak shifts in
15N/1H-HSQC spectra, hence a similar nearest-peak analysis was
carried out for b′x with b′x +-somatostatin.
The minimal chemical shift changes seen for the backbone
amide resonances of bb′ generated by comparing spectra for bb′x
with bb′ +-somatostatin are shown in Figure 3(a). The data
show that the majority of the chemical shift perturbation maps
to the b′ domain, a finding consistent with the b′ domain
containing the ligand-binding site [7,8]. In general, the
background level of chemical shift change is much higher in b′
than in b, suggesting some global movement or behaviour change
within the structure; however, the most substantial changes are
seen in the regions Glu222–Ile240, Leu270–Phe271, Leu300–Thr302,
Tyr310–Lys311 and a number of residues at the C-terminus (e.g.
Cys326 and Arg328). A very similar pattern of shifts is seen for the
comparisons between b′x and b′ + KFWWFS (Figure 3b), and b′x
and b′x +-somatostatin (Figure 3c), although the magnitude of
the shifts for the most perturbed residues in both analyses appears
to be somewhat diminished. The comparison of b′x with b′x +-
somatostatin is the only comparison where the analysis includes
the x-linker region (this region was omitted from the other two
analyses as it is absent in the liganded construct). Chemical shift
Figure 3 Chemical shift perturbation (to nearest peak) for backbone amide
1HN and 15N resonances of (a) bb′x compared with bb′ +-somatostatin,
and mapped on to the crystal structure of b′x (d), (b) b′x compared with
b′ +KFWWKS and (c) b′x compared with b′x+-somatostatin
Where the x-linker region was not part of the liganded construct [comparisons (a) and (b)],
this region was removed from the nearest-peak analysis. Chemical shifts for the bound form of
x were used for comparison (c). The magnitude of the chemical shift change was determined
as |1HN| + |15N/6| and the domain boundaries are shown by the vertical broken lines.
(d) Perturbed residues from bb′x compared with bb′ +-somatostatin (a) mapped on to the
crystal structure of b′x [20] (yellow, >0.13 p.p.m.; red, >0.2 p.p.m.). The x-linker region is
shown in grey. Figure produced using MOLMOL [35].
perturbations are seen in the x-linker region on the addition of
-somatostatin to b′x (Figure 3c), which is consistent with x
being displaced by the peptide ligand. Peaks with significant shifts
in the x-linker region are Ile334–Asp348. This stretch of residues
comprises the majority of the x-linker region and includes a
β-strand that forms an antiparallel connection with β5 in the
core β-sheet. Corresponding chemical shift changes are seen in
β5 (Met307–Tyr310) when x is displaced from the ligand-binding
site by -somatostatin.
The shifted residues in Figure 3(a) are shown mapped on a
ribbon diagram of the crystal structure of b′x in Figure 3(d). Those
residues showing the greatest backbone amide shifts are shown
in red, whereas those with moderate shifts are shown in yellow.
The analysis reveals that the majority of the shifted residues are
in the vicinity of where x contacts the b′ domain; Thr238, Ile240,
Leu270, Phe271, Leu300–Thr302 and Tyr310 are in the β-sheet that
forms the floor of the binding site, and Ala228 and Phe232 form the
c© The Authors Journal compilation c© 2009 Biochemical Society
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Figure 4 Perturbation of the indole resonances of Trp347 from b′x in the
presence of increasing concentrations of -somatostatin
Black, no -somatostatin; blue, 0.18 mM -somatostatin (0.7:1 molar ratio to b′x); green,
0.76 mM -somatostatin (1.9:1 molar ratio to b′x); red, 0.9 mM -somatostatin (3.0:1 molar
ratio to b′x). The high-field peak (1HN = 10.12 p.p.m.) is generated by the uncapped form of
b′x where the x-linker region is believed to be unbound, whereas the low-field resonance
(1HN = 10.39 p.p.m. in the absence of -somatostatin) is the capped form of the protein where
the x-linker region is bound in the ligand-binding site. All four spectra show an overlaid signal
for the uncapped form (far-right-hand peak) which results from small amounts of b′x dimer in
the samples.
face of α1 that borders the C-terminal end of the binding site.
Moderate shifts are also seen at the base of α4 that continues
into the x-linker region; chemical shift changes between bb′x
and bb′ +-somatostatin in this region may not reflect ligand
binding, but may be a direct consequence of x truncation in the
bb′ construct.
Effect of ligand binding on x
The x-linker region contains a unique tryptophan residue (Trp347)
and the indole cross-peak from this tryptophan side chain was
used previously to detect the difference in environment of the
x-linker region between the ‘capped’ and ‘uncapped’ forms of
the b′x domain [20]. Samples of capped b′x typically contain
a small proportion of uncapped dimeric material and hence
two peaks for the tryptophan indole are seen (Figure 2a). The
low-field cross-peak (1HN = 10.39p.p.m.) is representative of
the monomeric capped conformer, and the sharper high-field
cross-peak (1HN = 10.12p.p.m.) representative of the uncapped
dimeric form. Interconversion between the two forms is very
slow as shown by the presence of two distinct indole peaks in
the HSQC spectra. The addition of -somatostatin to samples
of (predominantly) monomeric b′x was seen to shift the capped
indole peak towards that of the uncapped form which remained
unchanged in position and appearance (Figure 4). Furthermore,
the degree of shift was dependent on the amount of -somatostatin
added to the sample. These results confirm that -somatost-
atin is able to displace x from the ligand-binding site and that the
tryptophan side chain in the capped monomer is in fast exchange
between two or more conformational states.
Chemical shifts of b and b′x compared with bb′x
NMR chemical shifts provide a convenient way of identifying
structural changes in the individual b and b′x domains when part
of the larger bb′x construct. The effect of b′x on the conformation
of b was investigated by comparing b peak positions in 15N/1H-
HSQC spectra of b alone and bb′x (Figure 5a); similarly, the effect
of b on b′x was investigated by comparing b′x peak positions in
spectra of b′x alone and bb′x (Figure 5b).
b′x had little effect on b outside of those residues in the
interface region. Residues Leu188–Arg196 and Leu219–Ala228 sensed
an environmental change (Figure 5a), but these regions map to the
turn between β4 and β5 which is in close proximity to b′ in the
bb′ structure (Figure 5c) and to a region which extends beyond
the domain boundary at Leu217. The lack of significant chemical
shift perturbations in b outside of the regions in close contact with
b′ suggests that the b domain is not structurally influenced by the
presence of b′.
In contrast, b′x, when together with b in the bb′x construct,
did show regions of backbone perturbation outside the immediate
interface site. The N-terminus (Lys213–Val220) includes the short
linker between the domains and is therefore part of the interface
site, but residues Thr279–Glu286 and Lys335–Gln350 also experienced
an environment change and are more distant from b (Figure 5b).
Thr279–Glu286 maps to α3 which forms part of the hydrophobic
binding site in b′ and Lys335–Glu350 maps to the x-linker region
that interacts at this site (Figure 5d). Their perturbation reports
on the binding of x and suggests that x behaves differently in
b′x compared with bb′x. Only backbone chemical shifts for the
unbound form of x could be assigned for bb′x so the perturbation
of x may reflect the bound/unbound nature of this region in the
two datasets. However, it is unlikely that the assignments for α3
are for the uncapped dimer form as these peaks would be expected
to be both broader and significantly weaker than the monomeric
capped form, since the uncapped dimer was only present at low
levels in the purified sample.
DISCUSSION
The key outcome from the present study is the definition of
ligand-binding residues in the b′ domain of human PDI, and
the demonstration that these are precisely the residues that
interact with the adjacent x-linker region of PDI in the ‘capped’
form of the b′x construct, supporting the conclusion that the
x-linker region gates ligand access to the principal binding
site on b′ [20]. However, this observation was dependent on
generating appropriate PDI preparations that gave well-resolved
NMR spectra, and this required detailed characterization of
several domain combinations and the resolution of multiple
forms. Hence the results also provide insights into the dynamics
and dimerization behaviour of PDI fragments containing the b′
domain.
Oligomerization and conformational flexibility of b′-containing
fragments
Previous work has shown that chemically homogeneous wild-
type b′x preparations contained more than one species, as
judged by intrinsic fluorescence [7,20]. We have now shown,
for both b′x and bb′x, that two forms can be separated and
characterized, a monomeric form that is predominantly in the
‘capped’ conformation and a dimeric form that is ‘uncapped’. In
contrast, recombinant b′ and bb′ fragments existed exclusively as
dimers when purified from E. coli cell lysates.
The line widths observed for the various b′ domain-containing
species analysed here are in the order b′ dimer>bb′ dimerbb′x
monomer>b′x monomer (see the legend to Figure 2), although
the molecular sizes are in the order bb′ dimerbb′x
monomer>b′ dimerb′x monomer. The anomalously broad line
c© The Authors Journal compilation c© 2009 Biochemical Society
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Figure 5 Chemical shift perturbation of backbone amide 1HN and 15N resonances of (a) b and (b) b′x in the bb′x di-domain construct compared with the
independent domains
The magnitude of the chemical shift change was determined as |1HN| + |15N/6|. Chemical shifts for the bound form of x were used in comparison (b) and the domain boundaries are shown
by vertical broken lines. (c and d) The residues perturbed in b and b′x are shown mapped on to the structure of bb′ from human PDI [21]. In (c), the regions Leu188–Arg196 and Leu219–Ala228
of b are shown in magenta and red respectively, in (d) the regions Lys213–Val220, Thr279–Glu286 and Lys335–Gln350 in b′x are shown in red, green and cyan respectively. The part of the di-domain
construct not directly involved in the comparison is drawn in light grey. (e) The residues perturbed in b′x are also shown mapped on to the crystal structure of b′x [20] to show their relationship
to x when bound in the ligand-binding site (residues are coloured according to (d) above; x is seen in cyan running horizontally across the β-sheet in the centre of the diagram). Figure produced
using MOLMOL [35].
widths observed for the b′ dimer suggest that the b′ domain is
in conformational exchange; line broadening is seen throughout
the b′ spectrum (Figure 2c), suggesting that this dynamic
flexibility affects all residues and is not ameliorated by homodimer
formation. Interestingly, the bb′ construct showed narrower line
widths than b′, even though it is twice the molecular size
of b′ and also forms a homodimer. It therefore appears that
the b domain is able to stabilize the b′ conformation and this
stabilization may occur partly through intermolecular interactions
within the bb′ dimer. The second crystal structure for yeast
Pdi1p represents a dimeric form of the full-length protein [14]
and shows intermolecular interactions between b and b′ domains
that include hydrophobic residues from the ligand-binding site.
Similar interactions within the human bb′ homodimer could
stabilize the structure and so account for the narrower line widths
seen for bb′ compared with b′. Conversely, our comparison of
NMR chemical shifts between the monomeric species b′x and
bb′x (see above) indicates direct effects of the b domain on the
adjacent b′ domain, so intramolecular stabilization effects may
also contribute to the differences in line width of b′ residues
between b′ and bb′. It is interesting to note, with regard to
the conformational flexibility observed for the b′ domain, that
structural disorder is a common feature of ligand-binding regions
of molecular chaperones [30].
The ligand-binding site in the b′ domain
The ligand-binding site of PDI has not been identified directly
from structure determination of PDI–ligand complexes, but
has been inferred from the ligand-binding activity of domain
combinations and mutants [7,8], and by the identification of
hydrophobic surface patches [13]. The site mapped in the present
study by chemical shift perturbation on ligand binding is in good
agreement with the hydrophobic site identified on the surface
of the b′ domain in the yeast Pdi1p structure (Figure 6). The
definition of the site mapped by chemical shift perturbation is
broader than that of the hydrophobic surface in Pdi1p, but this
reflects the nature of the analysis where the perturbation data
highlight changes to the environment of the protein backbone
as sensed by the 1HN and 15N amide nuclei and not directly by
the side chains. It is now clear that the site where peptide ligands
bind is also the site where the x-linker interacts in the b′x structure
[20]. This finding further supports the idea that the x-linker region
could act to gate access to the ligand-binding site in human PDI
just as the C-terminal region of ERp44 has been shown to cap the
ligand-binding site of this PDI family member and compete with
exogenous peptide ligands [17].
-Somatostatin was shown to compete with x for the ligand-
binding site on b′ (Figure 4). The NMR results suggest that
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Figure 6 Structural alignment of the b′ domain of human and yeast PDI
showing the ligand-binding site as mapped by chemical shift perturbation
(a) Comparison of bb′x with bb′ +-somatostatin (light grey, >0.13 p.p.m.; mid-grey,
>0.2 p.p.m.). (b) Comparison of b′x with b′ + KFWWFS (light grey, >0.15 p.p.m.; mid-
grey,>0.2 p.p.m.). (c) Comparison ofb′xwithb′x+-somatostatin (light grey,>0.09 p.p.m.;
mid-grey, >0.15 p.p.m.). (d) Comparison of bb′x with bb′ as assigned by Denisov et al. [31]
(light grey, >0.15 p.p.m.; mid-grey, >0.3 p.p.m.). (e) Chemical shift perturbation seen for bb′
binding to unfolded RNase [21]. (f) Hydrophobic ligand-binding site identified in the crystal
structure of yeast PDI (mid-grey shading). The secondary-structure assignments for both the
human and yeast structures are shown above and below the corresponding sequence. h, α-helix;
s, β-sheet.
the binding of x is in fast exchange on the NMR timescale as
a chemical shift titration producing an averaged peak position
is seen for the tryptophan indole resonance upon addition of
ligand. The competing ligand changes the proportion of bound and
unbound forms of x and so shifts the averaged peak position. The
indole peak in different peptide ligand concentrations is seen to
shift in a line between the unbound conformation (assumed to have
the same 15N and 1HN resonances as the uncapped contaminant)
and the maximally capped form seen when no competing ligand is
present. The proposed fast-exchange properties of the tryptophan
indole peak are consistent with our finding that this resonance
is virtually devoid of NOEs (nuclear Overhauser effects) to
other residues in the protein in a 15N-edited NOESY experiment.
Exchange of x between two or more forms would broaden any
NOESY signals and so make them difficult to detect. From the
data presented in Figure 4, the dissociation constant for the b′x–
-somatostatin complex is in the range 0.1–1.0 mM. This affinity
is similar to that of mastoparan (0.13 mM), and slightly weaker
than the related peptide somatostatin (0.035 mM), binding to a
fragment of PDI containing b and b′ domains ([21]; and further
description of the construct below). Sites elsewhere in the full-
length protein, such as those identified around the redox-active
sites in the a and a′ domains [13], will contribute significantly
to the overall binding affinity of PDI to larger unfolded protein
substrates.
Comparison with data from an alternative construct
Purification and NMR structural data have recently been published
for a construct of human PDI that is intermediate in length between
the bb′ and bb′x constructs described in the present study. The
Figure 7 Chemical shift differencemap for the backbone amide resonances
of bb′x (the present study) and bb′ (as assigned by Denisov et al. [31])
The bb′ construct contains the first eight residues of the x-linker region which is insufficient to
extend into the hydrophobic ligand-binding site. The magnitude of the chemical shift change was
determined as |1HN| + |15N/6|, and the domain boundaries are shown by vertical broken
lines.
protein investigated by Denisov et al. [21] comprises the bb′
domains and extends for an additional eight residues at the C-
terminus compared with the bb′ fragment in the present study,
thus including approximately half of the x-linker region [21].
This construct (extended bb′ or truncated bb′x?) was isolated
as monomeric and dimeric species that could be separated by
gel-filtration chromatography; therefore the first eight residues of
x are sufficient for the stable formation of the monomeric form.
Interestingly, the first eight residues of x include a β-strand known
to make antiparallel interactions with the core β-sheet of the b′
domain [20]; however, this strand is not evident in the NMR
structure determined for the extended bb′ construct [21]. It is
likely that this strand forms only transiently, or not at all, without
the additional stabilizing interactions made by the second half
of the x-linker region [20].
The monomeric form of the extended bb′ construct gave NMR
spectra of similar resolution to those found by us for bb′x, as
judged by simple comparison of 15N/1H-HSQC data (Figure 2b
and [31]). Comparison of the published backbone assignments
for the extended bb′ fragment [31] with our data for bb′x showed
a close agreement except for the regions known to be involved in
the interaction with x in the capped conformer (Figure 7). This is
to be expected, as the bb′ fragment does not possess the second
half of the x-linker region that interacts with the hydrophobic
ligand-binding site; hence a comparison is being made between
structures where x is bound and unbound. The regions that show
the greatest difference are Arg283–Phe287, Met307–Tyr310 and Glu316.
These regions map to α3 which interacts with x in the ligand-
binding site and the β-strand (Met307–Lys311) which forms an
antiparallel interaction with the first half of x in bb′x, but not in
bb′ (see the previous paragraph).
The backbone assignments for the extended bb′ construct show
two separate pathways from Lys333, the start of the x-linker region
[31]. This finding is consistent with our findings for b′x and bb′x
and suggests that the shortened x-linker region of this construct
exists in more than one conformation, as we have observed for
b′x and bb′x.
Denisov et al. [21] have also mapped the ligand-binding site
on their extended bb′ construct of human PDI using chemical
shift perturbation and employing -somatostatin, mastoparan and
‘scrambled’ RNase as ligands. The site defined in their work is
very similar to ours (see Figure 6 for a direct comparison). The
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Figure 8 Interactions of the hydrophobic ligand-binding site of the b′
domain of PDI
The example given here is for the b′x construct. The peptide ligand (black) is able to displace the
x-linker region (white) from the hydrophobic binding site (grey). Uncontrolled exposure of the
binding site is likely to result in homodimerization; a conformation seen for all the b′-containing
constructs of the present study. The binding of x to the hydrophobic binding site prevents dimer
formation and hence the in vitro rate of conversion of capped monomer into uncapped dimer
was found to be very low. An ‘uncapped monomer’ state is presumed to exist as a transient
intermediate between the monomer states depicted (capped, ligand-bound) and the uncapped
dimer, but it is not shown since we have no evidence that it exists in detectable quantities under
the conditions we have studied.
most significant difference between the datasets is that Denisov
et al. [21] observed chemical shift changes in α3 which runs
along the top of the ligand-binding site as shown in Figure 5(d),
whereas we saw very few shifts in this region (with the exception
of Asn281 and Leu285). The lack of perturbation in the present study
suggests that there is limited environmental change sensed by the
protein backbone in this region when x is displaced by a peptide
ligand (as in the present study) compared with when a ligand is
bound directly by a ‘naked’ domain where the x-linker region
is truncated.
Control of access to the binding site on the b′ domain of PDI
Chaperones and folding catalysts face an issue concerning how to
control exposure of the hydrophobic sites by which they interact
with their substrates. If such a site is fully exposed, then there
is a clear risk of uncontrolled binding, and the possibility of
dimerization and even aggregation. One strategy to avoid these
problems might be for such a site to be capped or otherwise
concealed in the absence of substrate. We do not have sufficient
structural information on a range of chaperones in the presence
and absence of their substrates to test this or to analyse the various
structural strategies by which it might be achieved. However,
in the case of PDI and ERp44, it does appear that the primary
ligand-binding site on the b′ domain is masked or ‘capped’ by
interaction with an adjacent mobile region. Binding of substrate
will then displace the ‘cap’ providing conditional access to the
binding site, which is never fully exposed. A cartoon depicting
the displacement of x by a peptide ligand from the substrate
binding site on b′x is shown in Figure 8. This model for PDI
and ERp44 is similar to that proposed for the Hsp70 (heat-
shock protein 70) family chaperones [32], where a hydrophobic
sequence that links the NBD (nucleotide-binding domain) to
the SBD (substrate-binding domain) has been observed in two
alternative conformations: an ‘out’ conformation in which the
linker is exposed to solvent, and an ‘in’ conformation in which
the linker is packed on to a hydrophobic patch on the SBD. In this
case, binding of ATP to the NBD is thought to act allosterically
to shift the balance between these two alternative conformations
of the interdomain linker and hence control the binding of ligands
to the SBD.
At this point, it is difficult to predict whether this strategy
of ligand displacement of a local ‘cap’ on the primary non-
covalent ligand-binding site will be a general theme among
members of the PDI family, as the current structural data on
complexes with ligands are sparse. There is a recent structure
of the ERp57–tapasin complex [18] and convincing models exist
for ERp57 interactions within the MHC peptide-loading complex
[18,33], and when bound to calnexin and a monoglucosylated
protein folding intermediate [12,34]. However, the role of ERp57
in these complexes is rather different from that of PDI which
we interpret as operating by using direct non-covalent binding
interactions with the substrate (mainly involving b′) to destabilize
the conformation of partially folded species while simultaneously
catalysing disulfide interchange in the substrate through covalent
interactions with the active sites in the a and a′ domains.
The work in the present study shows that b′ is a confor-
mationally active domain that forms homodimers unless peptide
ligands or the x-linker region are bound at its hydrophobic ligand-
binding site. Ligand and x binding dissociate the dimer form and
stabilize the tertiary structure. The binding of x is competitive
with ligands and in fast exchange between two or more states.
Controlled exposure of the hydrophobic binding site and the
conformational properties of b′ are likely to be key to the function
of PDI. The x-linker region provides a mechanism for controlling
access to the hydrophobic binding site and its displacement by
substrate could initiate rearrangement of the domain architecture
of PDI triggering changes in the protein folding activity by
coupling the non-covalent substrate interactions at the b′ domain
with covalent substrate interactions with the redox-active sites on
the a and a′ domains. What is now required is to define better by
both direct and indirect approaches, how ligand binding affects
the relative orientations and dynamics of the various domains and
sites within PDI.
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